Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Top Cited Papers
- 31 August 2017
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (9), 809-818
- https://doi.org/10.1056/nejmoa1703068
Abstract
Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.This publication has 16 references indexed in Scilit:
- Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia ABlood, 2016
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia AThe New England Journal of Medicine, 2016
- World Medical Association Declaration of HelsinkiJama-Journal Of The American Medical Association, 2013
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- Factor VIII inhibitors in hemophilia A: rationale and latest evidenceTherapeutic Advances in Hematology, 2012
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- Physical Functioning in Boys with Hemophilia in the U.S.American Journal of Preventive Medicine, 2011
- Articular status of haemophilia patients with inhibitorsHaemophilia, 2008
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- The Hemophilias — From Royal Genes to Gene TherapyThe New England Journal of Medicine, 2001